![](https://www.procure.ca/wp-content/uploads/85-sante_canada_en-250x167.jpg)
Health Canada Approves New Indication for Castration-Resistant Prostate Cancer
New Indication for the Use of Xtandi® (enzalutamide) Capsules Approval based on improved overall survival, delayed time to radiographic progression and an overall positive risk-benefit profile In the Phase III PREVAIL trial, men receiving enzalutamide therapy exhibited a statistically significant improvement in both overall survival and delayed time to radiographic progression or death as compared to